Cookie policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read our Privacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Ultimaster Clinical Program

07/09/2018 - Global

A comprehensive clinical program


Assessment of ‘safety’ refers to the side-effect profile and clinical events experienced (eg stroke, myocardial infarction, unplanned revascularisation). BMS, bare-metal stent; DAPT, dual antiplatelet therapy; MACCE, major adverse cardiac and cerebral events; MACE, major adverse coronary events; MCB, major or clinically relevant non-major bleeding; NACE, net adverse clinical endpoints; OFDI, optical frequency domain imaging; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TLF, target lesion failure. 

A remarkable 16 CE marked indications


Data on file: Ultimaster clinical data for specific indications, Annex to PS-6079, Clinical evaluation report, prepared November 2016; Data on file at Terumo Europe 

Consistent good safety* data at 1 year from controlled clinical trials12 and routine clinical practice13


Sustained long-term safety from controlled clinical trials14



  1. Stojkovic S et al. Fundam Clin Pharmacol 2014;29:95–105; 
  2. Barbato E et al. EuroIntervention 2015;11:541–8; 
  3. Beleslin B. Presented at EuroPCR 2017, abstract OP0028; 
  4. Saito S et al. Eur Heart J 2014;35:2021–31; 
  5. Data on file at Terumo Europe; 
  6. Valdes-Chavarri M. Presented at PCR 2016; 
  7. Chevalier B et al. Circ Cardiovasc Interv 2017;10:pii:e004801:doi:10.1161/CIRCINTERVENTIONS.116.004801; 
  8. Saito S et al Cardiovasc Interv Ther 2018;doi: 10.1007/s12928-018-0511-3; 
  9. e-ULTIMASTER trial. Available at: (accessed July2018); 
  10. Polad J. Presented at PCR2017, abstract POS0688; 
  11. MASTER DAPT trial. Available at (accessed July 2018).
  12. Internal report ISCD-523-37-20 - Report-CEII-1year results
  13. Internal report ISCD-523-37-19 - Report-eUM-Interim analysis
  14. Saito et al. - Presented at EuroPCR2018